Benzophenanthridine Alkaloid Chelerythrine Elicits Necroptosis of Gastric Cancer Cells via Selective Conjugation at the Redox Hyperreactive C-Terminal Sec498 Residue of Cytosolic Selenoprotein Thioredoxin Reductase

Targeting thioredoxin reductase (TXNRD) with low-weight molecules is emerging as a high-efficacy anti-cancer strategy in chemotherapy. Sanguinarine has been reported to inhibit the activity of TXNRD1, indicating that benzophenanthridine alkaloid is a fascinating chemical entity in the field of TXNRD1 inhibitors. In this study, the inhibition of three benzophenanthridine alkaloids, including chelerythrine, sanguinarine, and nitidine, on recombinant TXNRD1 was investigated, and their anti-cancer mechanisms were revealed using three gastric cancer cell lines. Chelerythrine and sanguinarine are more potent inhibitors of TXNRD1 than nitidine, and the inhibitory effects take place in a dose- and time-dependent manner. Site-directed mutagenesis of TXNRD1 and in vitro inhibition analysis proved that chelerythrine or sanguinarine is primarily bound to the Sec498 residue of the enzyme, but the neighboring Cys497 and remaining N-terminal redox-active cysteines could also be modified after the conjugation of Sec498. With high similarity to sanguinarine, chelerythrine exhibited cytotoxic effects on multiple gastric cancer cell lines and suppressed the proliferation of tumor spheroids derived from NCI-N87 cells. Chelerythrine elevated cellular levels of reactive oxygen species (ROS) and induced endoplasmic reticulum (ER) stress. Moreover, the ROS induced by chelerythrine could be completely suppressed by the addition of N-acetyl-L-cysteine (NAC), and the same is true for sanguinarine. Notably, Nec-1, an RIPK1 inhibitor, rescued the chelerythrine-induced rapid cell death, indicating that chelerythrine triggers necroptosis in gastric cancer cells. Taken together, this study demonstrates that chelerythrine is a novel inhibitor of TXNRD1 by targeting Sec498 and possessing high anti-tumor properties on multiple gastric cancer cell lines by eliciting necroptosis.

[1]  P. Wang,et al.  Necroptosis signaling and mitochondrial dysfunction cross-talking facilitate cell death mediated by chelerythrine in glioma. , 2023, Free Radical Biology & Medicine.

[2]  T. Heo,et al.  Chelerythrine, a novel small molecule targeting IL-2, inhibits melanoma progression by blocking the interaction between IL-2 and its receptor. , 2023, Life sciences.

[3]  D. Pratt,et al.  Ferroptosis: A flexible constellation of related biochemical mechanisms. , 2023, Molecular cell.

[4]  Xia Lin,et al.  Protein phosphatase PPM1A inhibition attenuates osteoarthritis via regulating TGF-β/Smad2 signaling in chondrocytes , 2023, JCI insight.

[5]  Meiyun Shi,et al.  Anti-Inflammatory Effect of Dimethyl Fumarate Associates with the Inhibition of Thioredoxin Reductase 1 in RAW 264.7 Cells , 2022, Molecules.

[6]  Penglong Wang,et al.  Natural Carrier-Free Binary Small Molecule Self-Assembled Hydrogel Synergize Antibacterial Effects and Promote Wound Healing by Inhibiting Virulence Factors and Alleviating the Inflammatory Response. , 2022, Small.

[7]  M. Santos-Silva,et al.  Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing , 2022, Comput. Biol. Medicine.

[8]  Yong Zhang,et al.  Nitidine chloride induces cardiac hypertrophy in mice by targeting autophagy-related 4B cysteine peptidase , 2022, Acta Pharmacologica Sinica.

[9]  B. Stockwell Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications , 2022, Cell.

[10]  Juan Zhang,et al.  Plasma thioredoxin reductase: a potential diagnostic biomarker for gastric cancer. , 2022, Carcinogenesis.

[11]  Wenqing Cai,et al.  Thioredoxin signaling pathways in cancer. , 2022, Antioxidants and Redox Signaling.

[12]  M. Conrad,et al.  Nutritional and Metabolic Control of Ferroptosis. , 2022, Annual review of nutrition.

[13]  Jianqiang Xu,et al.  Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin , 2022, Antioxidants.

[14]  Diego Muñoz,et al.  Natural isoquinoline alkaloids: Pharmacological features and multi-target potential for complex diseases. , 2022, Pharmacological research.

[15]  K. Vousden,et al.  The role of ROS in tumour development and progression , 2022, Nature Reviews Cancer.

[16]  Q. Ma,et al.  Plumbagin reduction by thioredoxin reductase 1 possesses synergy effects with GLUT1 inhibitor on KEAP1-mutant NSCLC cells. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[17]  Yue Zhang,et al.  Thioredoxin reductase 1 inhibitor shikonin promotes cell necroptosis via SecTRAPs generation and oxygen-coupled redox cycling. , 2021, Free radical biology & medicine.

[18]  D. Gelain,et al.  Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer. , 2021, Free radical biology & medicine.

[19]  H. M. Cochemé,et al.  Redox metabolism: ROS as specific molecular regulators of cell signaling and function. , 2021, Molecular cell.

[20]  L. Torrente,et al.  Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges. , 2021, Annual review of pharmacology and toxicology.

[21]  Christos T. Chasapis,et al.  Thioredoxin Reductase as a Pharmacological Target. , 2021, Pharmacological research.

[22]  Elias S. J. Arnér,et al.  Thioredoxin Reductase Inhibition for Cancer Therapy. , 2021, Annual review of pharmacology and toxicology.

[23]  Y. Saunthararajah,et al.  Thioredoxin Reductase is a major regulator of metabolism in leukemia cells , 2021, Oncogene.

[24]  Q. Ma,et al.  Menadione inhibits thioredoxin reductase 1 via arylation at the Sec498 residue and enhances both NADPH oxidation and superoxide production in Sec498 to Cys498 substitution. , 2021, Free radical biology & medicine.

[25]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[26]  R. Dreier,et al.  Review: ER stress-induced cell death in osteoarthritic cartilage. , 2020, Cellular signalling.

[27]  Jianguo Fang,et al.  Natural Molecules Targeting Thioredoxin System and Their Therapeutic Potentials. , 2020, Antioxidants & redox signaling.

[28]  F. Gnad,et al.  NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes , 2020, Clinical Cancer Research.

[29]  Ash A. Alizadeh,et al.  KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition. , 2020, Cancer discovery.

[30]  Jianguo Fang,et al.  Small molecules regulating reactive oxygen species homeostasis for cancer therapy , 2020, Medicinal research reviews.

[31]  Elias S. J. Arnér Effects of Mammalian Thioredoxin Reductase Inhibitors. , 2020, Handbook of experimental pharmacology.

[32]  T. Liang,et al.  Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms , 2020, Signal Transduction and Targeted Therapy.

[33]  K. Tew,et al.  Oxidative Stress in Cancer. , 2020, Cancer cell.

[34]  D. Sokaras,et al.  Direct Observation of Methylmercury and Auranofin Binding to Selenocysteine in Thioredoxin Reductase. , 2020, Inorganic chemistry.

[35]  Jianguo Fang,et al.  Sanguinarine as a new chemical entity of thioredoxin reductase inhibitor to elicit oxidative stress and promote tumor cell apoptosis. , 2020, Free radical biology & medicine.

[36]  Yanmin Zhang,et al.  Sanguinarine suppresses migration and metastasis in colorectal carcinoma associated with the inversion of EMT through the Wnt/β‐catenin signaling , 2020, Clinical and translational medicine.

[37]  A. Ullah,et al.  Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma , 2019, Cell Death & Disease.

[38]  Xiaobin Wu,et al.  ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin , 2019, Cell Death & Disease.

[39]  Jie Tian,et al.  p53-dependent upregulation of miR-16-2 by sanguinarine induces cell cycle arrest and apoptosis in hepatocellular carcinoma. , 2019, Cancer letters.

[40]  S. Eriksson,et al.  TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy , 2019, Proceedings of the National Academy of Sciences.

[41]  B. Stockwell,et al.  The Hallmarks of Ferroptosis , 2019, Annual Review of Cancer Biology.

[42]  M. Simon,et al.  Glutathione metabolism in cancer progression and treatment resistance , 2018, The Journal of cell biology.

[43]  Yundai Chen,et al.  Ripk3 promotes ER stress-induced necroptosis in cardiac IR injury: A mechanism involving calcium overload/XO/ROS/mPTP pathway , 2018, Redox biology.

[44]  Anton Simeonov,et al.  Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy , 2018, Science Translational Medicine.

[45]  Elias S. J. Arnér,et al.  The A to Z of modulated cell patterning by mammalian thioredoxin reductases , 2018, Free radical biology & medicine.

[46]  Matthew P. Taylor,et al.  Hepatocyte Hyperproliferation upon Liver-Specific Co-disruption of Thioredoxin-1, Thioredoxin Reductase-1, and Glutathione Reductase , 2017, Cell reports.

[47]  P. Zou,et al.  Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer. , 2016, Cancer letters.

[48]  Elias S. J. Arnér,et al.  Details in the catalytic mechanism of mammalian thioredoxin reductase 1 revealed using point mutations and juglone-coupled enzyme activities. , 2016, Free radical biology & medicine.

[49]  Jianguo Fang,et al.  Targeting Thioredoxin Reductase by Parthenolide Contributes to Inducing Apoptosis of HeLa Cells* , 2016, The Journal of Biological Chemistry.

[50]  S. Inoue,et al.  Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. , 2015, Cancer cell.

[51]  Y. Lindqvist,et al.  The conserved Trp114 residue of thioredoxin reductase 1 has a redox sensor-like function triggering oligomerization and crosslinking upon oxidative stress related to cell death , 2015, Cell Death and Disease.

[52]  P. Vandenabeele,et al.  Endoplasmic reticulum stress induces ligand-independent TNFR1-mediated necroptosis in L929 cells , 2015, Cell Death and Disease.

[53]  Jianguo Fang,et al.  Shikonin targets cytosolic thioredoxin reductase to induce ROS-mediated apoptosis in human promyelocytic leukemia HL-60 cells. , 2014, Free radical biology & medicine.

[54]  Jianguo Fang,et al.  Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase. , 2014, Free radical biology & medicine.

[55]  R. Hondal,et al.  Selenium as an Electron Acceptor during the Catalytic Mechanism of Thioredoxin Reductase , 2014, Biochemistry.

[56]  A. Holmgren,et al.  The thioredoxin antioxidant system. , 2014, Free radical biology & medicine.

[57]  H. E. Marshall,et al.  Thioredoxin-mediated Denitrosylation Regulates Cytokine-induced Nuclear Factor κB (NF-κB) Activation* , 2013, The Journal of Biological Chemistry.

[58]  C. V. van Blitterswijk,et al.  Spheroid culture as a tool for creating 3D complex tissues. , 2013, Trends in biotechnology.

[59]  A. Holmgren,et al.  Glutathione and Glutaredoxin Act as a Backup of Human Thioredoxin Reductase 1 to Reduce Thioredoxin 1 Preventing Cell Death by Aurothioglucose* , 2012, The Journal of Biological Chemistry.

[60]  K. Fritz-Wolf,et al.  Crystal structure of the human thioredoxin reductase-thioredoxin complex. , 2011, Nature communications.

[61]  X. Qian,et al.  Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate. , 2010, Free radical biology & medicine.

[62]  Elias S. J. Arnér Focus on mammalian thioredoxin reductases--important selenoproteins with versatile functions. , 2009, Biochimica et biophysica acta.

[63]  A. Holmgren,et al.  Molecular Mechanisms of Thioredoxin and Glutaredoxin as Hydrogen Donors for Mammalian S Phase Ribonucleotide Reductase* , 2009, Journal of Biological Chemistry.

[64]  Elias S. J. Arnér,et al.  Cell Death by SecTRAPs: Thioredoxin Reductase as a Prooxidant Killer of Cells , 2008, PloS one.

[65]  A. Holmgren,et al.  Ebselen: A thioredoxin reductase-dependent catalyst for α-tocopherol quinone reduction , 2005 .

[66]  Elias S. J. Arnér,et al.  Measurement of Thioredoxin and Thioredoxin Reductase , 2005, Current protocols in toxicology.

[67]  T. Belyaeva,et al.  Sensitivity of lysosomal enzymes to the plant alkaloid sanguinarine: comparison with other SH‐specific agents , 2003, Cell biology international.

[68]  Elias S. J. Arnér,et al.  Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[69]  A. Böck,et al.  High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes. , 1999, Journal of molecular biology.

[70]  T. Stadtman,et al.  Heparin-binding properties of selenium-containing thioredoxin reductase from HeLa cells and human lung adenocarcinoma cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[71]  J. Ulrichová,et al.  Inhibition of liver alanine aminotransferase activity by some benzophenanthridine alkaloids. , 1981, Journal of medicinal chemistry.

[72]  A. Holmgren,et al.  Ebselen: a thioredoxin reductase-dependent catalyst for alpha-tocopherol quinone reduction. , 2005, Toxicology and applied pharmacology.